Torrey Pines Therapeutics Permitted to Begin Phase III Trial of Migraine Drug

Xconomy San Diego — 

Torrey Pines Therapeutics said today that the FDA has agreed to let it conduct a final-stage clinical trial of tezempanel for acute migraine headaches. The pivotal trial will examine tezempanel at a 40 milligram and a lower dose, while also monitoring patients for any heart irregularities known as QT prolongation. The timing of the trial will depend on when the La Jolla, CA-based company (NASDAQ: TPTX) can find a partner or raise cash.